Clinical trials
Adverse Event clinical trials
Below are recruiting adverse event clinical trials, each written for real people, not researchers. We’re tracking 191 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06860542RecruitingPhase 2
Inhaled steroid to prevent lung inflammation from returning after immunotherapy
This trial tests whether using an inhaled steroid (budesonide) can help prevent lung inflammation (pneumonitis) from coming back in people who have had it caused by immunotherapy cancer treatment. It may be an option for patients who need extra support after their first bout of this side effect.
Calgary, AlbertaAges 18 years+ - NCT07291232RecruitingPhase 1
Study of an injected drug for adults with obesity
This study tests an injected medication called ABBV-295 for adults with obesity. The goal is to see how safe it is and how the body processes it. You may join if you have a BMI between 30 and 45 and are generally healthy, and you haven't been on other weight loss treatments recently.
Anaheim, CaliforniaAges 18–65 - NCT07306832RecruitingPhase 1
Study of IV Pivekimab Sunirine for Children with Relapsed AML
This study tests an experimental IV drug called pivekimab sunirine for children whose acute myeloid leukemia (AML) has returned or not responded to previous treatments. The drug targets a specific marker on leukemia cells (CD123) to try to kill them.
Palo Alto, CaliforniaAges 6 months–17 years - NCT07155174RecruitingPhase 2
Testing new drug combo for first-line extensive small cell lung cancer
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
New Haven, ConnecticutAges 18 years+ - NCT07365241RecruitingPhase 3
Study of ABBV-706 vs standard care for advanced small cell lung cancer
This trial tests a new drug called ABBV-706 against standard treatments (topotecan, lurbinectedin, or amrubicin) for people with small cell lung cancer that has come back or stopped responding to previous therapies. The goal is to see if ABBV-706 works better at controlling the cancer.
Birmingham, AlabamaAges 18 years+ - NCT06461897RecruitingPhase 3
Comparing upadacitinib to dupilumab for eczema in children
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
Little Rock, ArkansasAges 2–11 - NCT06438588Recruiting
Fasting-mimicking diet to reduce immunotherapy side effects
This trial tests whether a special low-calorie 'fasting-mimicking' diet can reduce side effects from common immunotherapy drugs for advanced cancer. If you're on a PD-1, PD-L1, or CTLA-4 inhibitor, this diet might help you feel better during treatment.
Jacksonville, FloridaAges 18 years+ - NCT06470971RecruitingPhase 2
Siltuximab to prevent severe side effects during immunotherapy rechallenge
This trial tests if siltuximab can prevent severe immune-related side effects when patients restart immunotherapy (anti-PD-1/PD-L1) after previous severe side effects. It aims to make rechallenge safer for people with advanced cancer.
Columbus, OhioAges 18 years+ - NCT05663775RecruitingPhase 2
Mesalamine to prevent bowel inflammation after melanoma immunotherapy
This study tests whether taking mesalamine can prevent colitis (bowel inflammation) in people with advanced melanoma who are treated with ipilimumab plus nivolumab. It may help reduce dangerous stomach or bowel side effects from this cancer treatment.
Edmonton, AlbertaAges 18 years+ - NCT05345821Recruiting
Study of side effects and satisfaction after silicone breast implants
This trial follows women who get their first breast implant surgery or a repeat (primary vs secondary) and records side effects and how satisfied they feel. It aims to better understand safety and satisfaction with smooth-surface silicone implants.
Santo André, São PauloAges 18 years+ - NCT04840355Recruiting
Monitoring safety of sintilimab in Chinese patients
This study carefully tracks how safe sintilimab is for people with cancer in real-world care. It may help your care team understand side effects and risks during treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT03356132Recruiting
Breast implant safety and satisfaction follow-up study
This study looks at side effects and satisfaction after breast implant surgery. It may help by sharing what problems happen most and how satisfied people feel after getting a Silimed® textured or Silimed foam-coated implant.
Niterói, Rio de JaneiroAges 18 years+ - NCT04777357RecruitingPhase 3
Cariprazine for bipolar depression in ages 10 to 17
This Phase 3 study tests whether cariprazine can improve depression symptoms in children and teens with bipolar I disorder, and also tracks side effects. It may help if your depressive episode is ongoing and you meet specific mood and screening score requirements.
Bentonville, ArkansasAges 10–17 - NCT05136950Recruiting
Tracking side effects after secondary lens surgery for cataracts
This study follows children who had congenital cataract surgery to see how often glaucoma-related side effects happen after getting a secondary intraocular lens. It may help doctors better prevent and catch eye pressure problems after these surgeries.
GuangzhouAges 1.5 years–14 years - NCT04226612Recruiting
Link between inpatient blood pressure and in-hospital complications
This study looks at whether higher or lower blood pressure during a hospital stay is associated with complications during the same stay. It may help doctors better identify risk and improve monitoring.
Guangzhou, GuangdongAges Any age - NCT05711394RecruitingPhase 3
Atogepant for preventing episodic migraine in children
This study tests whether an oral medicine called atogepant can reduce migraine activity in children ages 6–17 and checks its side effects. It’s meant for kids with episodic migraine (not the more constant types) who may benefit from preventive treatment.
Huntsville, AlabamaAges 6–17 - NCT06693440Recruiting
How PD-1 antibody therapy affects immune function in cancer
This trial is studying how PD-1 antibody therapy (a type of immunotherapy that helps your immune system fight cancer) affects the immune system in people with various cancers. It may be a good fit if you have a confirmed cancer diagnosis and have your medical records and immune test results available.
Zhengzhou, HenanAges 18 years+ - NCT06702566Recruiting
Study of Ferritin in Immune-Related Side Effects
This study looks at how a blood marker called ferritin relates to side effects from immunotherapy or other cancer treatments. It may help doctors predict and manage those side effects better.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07220460RecruitingPhase 2
Study of an oral drug for bipolar depression
This trial tests an experimental pill (ABB-932) for people with bipolar I or II disorder who are currently in a depressive episode. The goal is to see if the drug is safe and helps improve mood.
Phoenix, ArizonaAges 18–65 - NCT07098351Recruiting
A trial for a new itchy skin medicine for people on peritoneal dialysis
This trial tests if a medication called nalfurafine hydrochloride (taken as a tablet that melts in your mouth) can help reduce moderate to severe itching in people receiving peritoneal dialysis for chronic kidney disease.
Guangzhou, GuangdongAges 18–85 - NCT05832606Recruiting
Food changes to reduce side effects from immunotherapy
This trial tests whether a specific food plan can reduce side effects (toxicity) from standard immunotherapy that targets PD-1 and/or CTLA-4. It may help people tolerate treatment better while staying on their usual cancer care.
JetteAges 18 years+ - NCT07673107RecruitingPhase 2
Botulinum toxin injection for essential tremor of hands and arms
This trial tests an investigational botulinum toxin injection (AGN-151607-DP) to reduce shaking in the hands and arms caused by essential tremor. It is for adults who have been diagnosed with this condition and who do not have certain nerve or muscle disorders.
Fresno, CaliforniaAges 18–85 - NCT07024238Enrolling by invitation
Short-chain fatty acid supplement for kidney transplant patients
This study tests whether taking a short-chain fatty acid (a type of fiber-like substance) supplement can improve gut health in people who have had a kidney transplant. It may help keep the transplant working well.
Martin, SlovakiaAges 18 years+ - NCT07477886Recruiting
Using room sensors to spot early warnings for hospitalized cancer patients
This study uses special sensors in patient rooms to monitor movement and other signals that might show early signs of medical problems. The goal is to see if these sensors can help doctors and nurses step in sooner for cancer patients in the hospital.
Rochester, MinnesotaAges 18 years+
Hear when a new Adverse Event trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adverse event?
- Yes. Clin2 currently lists 191 recruiting adverse event studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adverse event trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adverse event trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.